Shire PLC (SHPG)

194.44
NASDAQ : Health Care
Prev Close 194.44
Day Low/High 0.00 / 0.00
52 Wk Low/High 147.60 / 270.63
Avg Volume 2.90M
Exchange NASDAQ
Shares Outstanding 197.38M
Market Cap 38.21B
EPS 6.60
P/E Ratio 52.61
Div & Yield 1.33 (0.70%)

Latest News

3 Stocks Pushing The Drugs Industry Downward

3 Stocks Pushing The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Shire Reinforces Commitment In Hematology With Robust Data Presented At International Congress Of The World Federation Of Hemophilia

Shire Reinforces Commitment In Hematology With Robust Data Presented At International Congress Of The World Federation Of Hemophilia

More than 40 presentations and sessions feature broad pipeline and proven factor replacement portfolio, with new innovation on outcomes, safety and efficacy measures

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

At least one company follower believes the divestiture of Shire's Neurology division for as much as $13 billion would be a logical next move.

3 Drugs Stocks Dragging The Industry Down

3 Drugs Stocks Dragging The Industry Down

TheStreet highlights 3 stocks pushing the health services industry lower today.

European Markets Mixed; Retailers and Automakers Advance

European Markets Mixed; Retailers and Automakers Advance

German consumer price data confirms inflation is accelerating; automakers rise on better-than-expected earnings.

July 12 Premarket Briefing: 10 Things You Should Know

July 12 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are pointing to a higher start for Wall Street on Tuesday following a record close for the S&P 500.

Pre-Market Activity Shows Gains For Shire (SHPG)

Pre-Market Activity Shows Gains For Shire (SHPG)

Trade-Ideas LLC identified Shire (SHPG) as a pre-market leader candidate

Shire’s Shares Rise on FDA Approval of Dry Eye Med

Shire’s Shares Rise on FDA Approval of Dry Eye Med

Jefferies estimates Xiidra could yield revenue of $1.5 billion within five years of its launch.

European Markets Mixed; Shire Gains on 'Blockbuster' Eye-Drop Clearance

European Markets Mixed; Shire Gains on 'Blockbuster' Eye-Drop Clearance

German consumer price data confirms inflation is accelerating, while in the U.K. a closely watched gauge of retail sales slows to a seven-year low.

S&P 500 Back in Positive for 2016 on Day Two of Rally

S&P 500 Back in Positive for 2016 on Day Two of Rally

The S&P 500 bounces back into positive territory for 2016 on Wednesday in day two of a post-Brexit comeback rally.

Stocks Hold Gains, Crude Climbs on Inventory Drop

Stocks Hold Gains, Crude Climbs on Inventory Drop

Stocks extend a post-Brexit rally into day two on Wednesday as investors see opportunity after a wave of selling at the beginning of the week.

Opening Bell: U.S. Stocks Rally as Brexit Fears Diminish; Shire Shares Gain

Opening Bell: U.S. Stocks Rally as Brexit Fears Diminish; Shire Shares Gain

U.S. stocks rose Wednesday, building on Tuesday's gains, as Brexit fears dissipated.

Stock Futures Point to Day Two of Post-Brexit Rally

Stock Futures Point to Day Two of Post-Brexit Rally

Stock futures push a rally into day two on Wednesday as the shock of Brexit continues to fade.

Shire and Glaxo Offer Prescription to London's Woes

Shire and Glaxo Offer Prescription to London's Woes

U.K.-listed drugs companies are likely to remain in rude health even if Britain stumbles post Brexit.

Today's Pre-Market Trading Very Positive For Shire (SHPG)

Today's Pre-Market Trading Very Positive For Shire (SHPG)

Trade-Ideas LLC identified Shire (SHPG) as a pre-market leader candidate

Trade-Ideas: Shire (SHPG) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas: Shire (SHPG) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Shire (SHPG) as a pre-market mover with heavy volume candidate

3 Stocks Pulling The Drugs Industry Downward

3 Stocks Pulling The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Shire (SHPG) Leads The Pack In Pre-Market Activity

Shire (SHPG) Leads The Pack In Pre-Market Activity

Trade-Ideas LLC identified Shire (SHPG) as a pre-market leader candidate

'Mad Money' Lightning Round: I'm Sticking With Southwest Airlines

'Mad Money' Lightning Round: I'm Sticking With Southwest Airlines

Cramer likes Altria and Philip Morris and says Freeport-McMoRan can't be killed.

Jim Cramer's 'Mad Money' Recap: Sit on the Sidelines for Now, Then Pounce

Jim Cramer's 'Mad Money' Recap: Sit on the Sidelines for Now, Then Pounce

The Fed, oil prices and the looming 'Brexit' vote are pushing stocks lower, Cramer says. Next week you'll find lots of bargains on quality names.

Shire And Kamada Announce FDA Approval Of Expanded Label For Self-infusion Of GLASSIA For The Treatment Of Emphysema Due To Severe AAT Deficiency

Shire And Kamada Announce FDA Approval Of Expanded Label For Self-infusion Of GLASSIA For The Treatment Of Emphysema Due To Severe AAT Deficiency

GLASSIA [Alpha-1 Proteinase Inhibitor (Human)] is the only FDA approved alpha-1 antitrypsin (AAT) augmentation treatment that patients can self-infuse at home